Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t(11;14). Despite its dependence on cyclin D1 ...

Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

for patients with mantle cell lymphoma (MCL) in remission following their initial treatment. The finding is from the phase 3 study EA4151, Rituximab With or Without Stem Cell Transplant in ...

China’s National Medical Products Administration (NMPA) has approved InnoCare Pharma’s Bruton's tyrosine kinase (BTK) ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

Roche has secured approval from the EC for Columvi plus GemOx combo to treat adults with R/R diffuse large B-cell lymphoma (DLBCL).

SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

is in development for CD5-positive hematologic malignancies including T-cell lymphoma, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia and mantle cell lymphoma. T-cell lymphomas, as ...

Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and ...